Virtu Financial LLC acquired a new position in shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 100,363 shares of the specialty pharmaceutical company’s stock, valued at approximately $442,000. Virtu Financial LLC owned 0.30% of Adamis Pharmaceuticals at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Granite Investment Partners LLC acquired a new stake in Adamis Pharmaceuticals during the 3rd quarter worth about $457,000. Advisor Group Inc. boosted its position in Adamis Pharmaceuticals by 149.9% during the 3rd quarter. Advisor Group Inc. now owns 56,001 shares of the specialty pharmaceutical company’s stock worth $292,000 after acquiring an additional 33,591 shares during the period. Vanguard Group Inc. boosted its position in Adamis Pharmaceuticals by 22.2% during the 2nd quarter. Vanguard Group Inc. now owns 942,940 shares of the specialty pharmaceutical company’s stock worth $4,903,000 after acquiring an additional 171,167 shares during the period. EAM Investors LLC boosted its position in Adamis Pharmaceuticals by 58.3% during the 3rd quarter. EAM Investors LLC now owns 371,732 shares of the specialty pharmaceutical company’s stock worth $1,942,000 after acquiring an additional 136,970 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Adamis Pharmaceuticals by 131.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 27,464 shares of the specialty pharmaceutical company’s stock worth $143,000 after acquiring an additional 15,577 shares during the period. Hedge funds and other institutional investors own 12.42% of the company’s stock.
Shares of Adamis Pharmaceuticals Corp (ADMP) traded down $0.10 during trading on Wednesday, hitting $3.70. The stock had a trading volume of 751,396 shares, compared to its average volume of 1,010,000. The company has a current ratio of 3.93, a quick ratio of 3.79 and a debt-to-equity ratio of 0.06. Adamis Pharmaceuticals Corp has a fifty-two week low of $2.35 and a fifty-two week high of $6.45. The firm has a market cap of $123.53, a price-to-earnings ratio of -5.29 and a beta of 0.36.
ADMP has been the subject of a number of research reports. B. Riley set a $10.00 price objective on Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, November 15th. Maxim Group set a $5.00 price objective on Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, February 14th. ValuEngine lowered Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 30th. Zacks Investment Research lowered Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 20th. Finally, Raymond James Financial set a $7.00 price target on Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Friday, February 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Adamis Pharmaceuticals has a consensus rating of “Hold” and an average target price of $7.33.
COPYRIGHT VIOLATION NOTICE: “Virtu Financial LLC Acquires Shares of 100,363 Adamis Pharmaceuticals Corp (ADMP)” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://ledgergazette.com/2018/03/14/virtu-financial-llc-purchases-new-stake-in-adamis-pharmaceuticals-corp-admp.html.
Adamis Pharmaceuticals Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.